Results 41 to 50 of about 1,741 (166)

Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction

ERJ Open Research
Background Persistent airflow obstruction (PAO) in patients with asthma can be difficult to treat. Tezepelumab blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis.
Elliot Israel, Mario Castro, Christopher S. Ambrose, Jean-Pierre Llanos, Nestor A. Molfino, Nicole L. Martin, Sandhia S. Ponnarambil, Neil Martin   +7 more
doaj   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Knowledge and practice regarding eosinophilic gastrointestinal disorders other than eosinophilic esophagitis among pediatric gastroenterologists of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

JPGN Reports, EarlyView.
Abstract Objective Evaluating clinical practices in the management of non‐esophageal eosinophilic gastrointestinal disorders (non‐EoE EGIDs) among pediatric gastroenterologists in Latin America. Methods A cross‐sectional descriptive study was conducted using a survey distributed via the REDCap platform.
Sofia Paz, Michelle Higuera Carrillo, Alonso Rafael Echavez Agudelo, Mário Cesar Vieira, Juan Pablo Riveros López, Natali González Rozó, Gustavo Javier Tagliaferro, Fabiola Sánchez Hernández, Catalina Ortiz Piedrahita, Wilson Daza Carreño, Ailim Margarita Carias Domínguez, José Fernando Vera Chamorro, Sabine Krüger Truppel, Maximiliano Fernández Rivas, César Augusto Moreno Serrano, Pablo Torres Córdova, Carlos Marcelo Timossi, Pablo Vásquez   +17 more
wiley   +1 more source

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR

Journal of Asthma and Allergy, 2023
Tanya M Laidlaw1,2 *, Andrew Menzies-Gow3 *, Scott Caveney,4 Joseph K Han,5 Nicole Martin,6,7 Elliot Israel,8 Jason K Lee,9,10 Jean-Pierre Llanos,11 Neil Martin,12,13 Ayman Megally,14 Bhavini Parikh,14 Sylvia Vong,15 Tobias Welte,16 Jonathan ...
Laidlaw TM, Menzies-Gow A, Caveney S, Han JK, Martin N, Israel E, Lee JK, Llanos JP, Martin N, Megally A, Parikh B, Vong S, Welte T, Corren J   +13 more
doaj  

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles

Respiratory Research
Background An increasing amount of evidence supports the relevance of epithelium across the wide spectrum of asthma pathobiology. On a clinical ground tezepelumab, selectively binding TSLP, a major epithelial cytokine, has demonstrated to be effective in
Marco Caminati, A. Vatrella, P. Rogliani, E. Carpagnano, A. Spanevello, G. Senna   +5 more
doaj   +1 more source

Comparative efficacy and safety of monoclonal antibodies biologic therapies for chronic rhinosinusitis with nasal polyps: A systematic review and network meta-analysis

American Journal of Otolaryngology
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a significant therapeutic challenge with high recurrence rates despite the current standard treatments.
Abdulhakeem Almutairi, Lina Yousef Aloraini, Bader Muzhier Alshahrani, Maan Omar Alzuhairi, Rabab Hussain Alzanadi, Khalid Fahad Alanazi, Yahya Ali Khubrani, Ahmed Y. Azzam   +7 more
doaj   +1 more source

Resolving Endoplasmic Reticulum‐Protein Misfolding Restores Corticosteroid Sensitivity in Experimental Models of Severe Asthma

Allergy, EarlyView.
This study investigates the role of ER stress in steroid resistance in severe asthma. Results from advanced 3D models of human bronchial epithelial cells, steroid‐resistant severe asthma mouse models, and human severe asthma sputum samples show that treatment with ICS in combination with the ER stress inhibitor 4‐PBA significantly enhances steroid ...
Prabuddha S. Pathinayake, Alexandra C. Brown, Nikhil T. Awatade, Philip M. Hansbro, Katherine J. Baines, Richard Y. Kim, Nathan W. Bartlett, Jay C. Horvat, Peter A. B. Wark   +8 more
wiley   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Positioning of Tezepelumab in Severe Asthma

Journal of Investigational Allergology and Clinical Immunology
Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress ...
J C, Miralles-López, D, Antolín-Amérigo, I, García-Moguel, J, Domínguez-Ortega, J, Delgado-Romero, S, Quirce   +5 more
openaire   +2 more sources